Bionet (1784) — Capital Reinvestment Ratio
Latest as of June 2026:
0.20x
Bionet (1784) has a Capital Reinvestment Ratio of 0.20x as of June 2026, meaning it reinvests 0% of its operating cash flow (NT$51.22 Million) in capital expenditures (NT$10.14 Million). Check 1784 tangible net worth ratio to evaluate the tangible quality of the company's equity base.
Capital Reinvestment Ratio
0.20x
Capex / Operating Cash Flow
Operating Cash Flow
NT$51.22 Million
TWD
Capital Expenditures
NT$10.14 Million
TWD
Data as of
Jun 2026
Most recent filing
Bionet Capital Reinvestment Ratio (2019–2025)
This chart tracks Bionet's Capital Reinvestment Ratio across 7 annual periods. For the full cash flow conversion analysis, see 1784 cash flow metrics.
Annual Capital Reinvestment Ratio for Bionet (2019–2025)
Year-by-year Capital Reinvestment Ratio for Bionet from 2019 to 2025. See Bionet free cash flow ratio to measure how efficiently the company converts operating cash flow to free cash.
| Year | Reinvestment Ratio | Operating CF (TWD) | Capital Expenditures | YoY Change |
|---|---|---|---|---|
| 2025 | 0.89x | NT$148.04 Million | NT$132.18 Million | ▲ +52.3% |
| 2024 | 0.59x | NT$176.49 Million | NT$103.49 Million | ▲ +241.5% |
| 2023 | 0.17x | NT$153.09 Million | NT$26.28 Million | ▼ -50.6% |
| 2022 | 0.35x | NT$94.65 Million | NT$32.91 Million | ▼ -71.0% |
| 2021 | 1.20x | NT$13.88 Million | NT$16.66 Million | ▲ +132.6% |
| 2020 | 0.52x | NT$73.66 Million | NT$38.03 Million | ▼ -88.1% |
| 2019 | 4.35x | NT$2.67 Million | NT$11.60 Million | — |
Capital Reinvestment Ratio = ABS(Capital Expenditures) / Operating Cash Flow